Bionical Emas is the only Contract Research Organization (CRO) to combine Clinical Development, Clinical Trial Supply (CTS) and Early Access Programs (EAP) bringing life-changing medicines to patients around the world.
Their unique integrated business model, with its range of services and capabilities, benefit many of the world’s leading pharma and biotech companies. This distinctive offering enables them to maximize access and generate evidence at every stage of the drug development pathway.
Bionical Emas has a dedicated Rare Disease Team that consists of Global Patient Advocacy and Rare Disease Insights Specialists who drive their strong focus on patient centricity and customize clinical development and early access programs, to ensure they are carefully designed to meet the nuances and requirements that a rare disease can present.
bionicalemas.com